# Testolone (RAD-140)

*Also known as: RAD-140, RAD*

Potent SARM; suppression and hepatotoxicity reported at higher doses.

## Overview

Testolone (RAD-140) is a non-steroidal selective androgen receptor modulator originally investigated for breast cancer cachexia and muscle-wasting conditions. It binds the androgen receptor with strong tissue selectivity, producing pronounced anabolic effects in muscle relative to androgenic action in prostate tissue. The compound has a roughly 44.7-hour half-life with peak concentration near 6 hours and about 60% bioavailability, so once-daily oral dosing is typical and accumulation occurs over the first week. Reported effects include rapid strength and lean mass increases, but the same potency drives measurable testosterone suppression, lipid disruption, and liver enzyme elevation at common off-label doses. As an investigational, unapproved compound that is WADA-prohibited, RAD-140 is often sold mislabeled or contaminated, so harm reduction centers on third-party testing, baseline and on-cycle bloodwork (LH, FSH, total T, lipids, ALT/AST), and a PCT plan.

## Pharmacokinetics

- **Model tier:** advanced
- **Half-life:** 1.9 days (44.7 hours)
- **Cmax:** 447 ng/mL
- **Tmax:** 0.3 days
- **Bioavailability:** 60%

## Dosing

- **Default dose:** 10 mg
- **Typical range:** 5–20 mg
- **Units:** ng/mL

## Harm reduction

- **Aromatizes:** No
- **Hepatotoxicity:** mild
- **Injection frequency:** Oral, daily

## Detection time (anti-doping)

- **Window:** 5–9 days post-last-dose
- **Target metabolite:** RAD-140 sulfate phase I metabolite
- **Assay:** LC-HRMS/MS
- **Notes:** Sulfate conjugate detectable ~6 days after microdose. Parent RAD-140 in plasma ≥8 days.

## Source

- **Label:** PubMed RAD-140 case
- **URL:** https://pubmed.ncbi.nlm.nih.gov/34565686/

---

**Canonical URL:** https://anabolicdex.com/compounds/testolone
**Plot:** https://anabolicdex.com/plot?compound=testolone